Kirk Nelson

1.6k citations

23 papers · 1.2k indexed · h-index 16

Impact in

Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 0.5%
- Antibiotic Use and Resistance

Papers in

Molecular Medicine 20
- Antibiotic Resistance in Bacteria 20
Pollution 9
- Pharmaceutical and Antibiotic Environmental Impacts 9

Co-authors: Debora Rubio-Aparicio Dongxu Sun Michael N. Dudley Ruslan Tsivkovski Olga Lomovskaya David C. Griffith Maxim Totrov Mark L. Cunningham
Journals: Antimicrobial Agents and Chemotherapy (10 papers)Open Forum Infectious Diseases (5 papers)Journal of Medicinal Chemistry (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)SLAS DISCOVERY (1 paper)
Partner nations: United States Thailand

In The Last Decade

Kirk Nelson

23 papers receiving 1.1k citations

Peers

Countries citing papers authored by Kirk Nelson

Since Specialization

Citations

This map shows the geographic impact of Kirk Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Nelson more than expected).

Fields of papers citing papers by Kirk Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Nelson. The network helps show where Kirk Nelson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kirk Nelson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kirk Nelson Line = papers co-authored together Kirk Nelson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia Journal of Medicinal Chemistry ·Robert L. Hudkins, Eric Allen, 娄加凤, Isaac Hoffman, C. Walker, Brenda Valero Díaz, Kirk Nelson, Мамед Сакитович Магарамов, Qing Ye, Jacqueline H. Starrett, Adelina Machado de Carvalho Nogueira, Todd J. Harris, Ronald V. Swanson, Daniel C. Bensen	2024	10
2	In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales Antimicrobial Agents and Chemotherapy ·Olga Lomovskaya, Mariana Castanheira, 美紀北川, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, Dongxu Sun, Maxim Totrov, Jeffery S. Loutit, Michael Dudley	2023	30
3	Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action Antimicrobial Agents and Chemotherapy ·Dongxu Sun, Ruslan Tsivkovski, Joe Pogliano, Hannah Tsunemoto, Kirk Nelson, Debora Rubio-Aparicio, Olga Lomovskaya	2022	29
4	In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy ·Olga Lomovskaya, Debora Rubio-Aparicio, Kirk Nelson, Dongxu Sun, Ruslan Tsivkovski, Mariana Castanheira, 美紀北川, Jeffery S. Loutit, Michael Dudley	2021	21
5	In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms Antimicrobial Agents and Chemotherapy ·Kirk Nelson, Debora Rubio-Aparicio, Dongxu Sun, Michael Dudley, Olga Lomovskaya	2020	37
6	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases Journal of Medicinal Chemistry ·Scott J. Hecker, K. Raja Reddy, Olga Lomovskaya, David C. Griffith, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, Dongxu Sun, Mojgan Sabet, Ziad Tarazi, Jonathan Parkinson, Maxim Totrov, Serge H. Boyer, Tomasz Glinka, O.A. Pemberton, Yu Chen, Michael N. Dudley	2020	158
7	Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in Enterobacteriaceae , Pseudomonas aeruginosa, and Acinetobacter baumannii Antimicrobial Agents and Chemotherapy ·Olga Lomovskaya, Kirk Nelson, Debora Rubio-Aparicio, Ruslan Tsivkovski, Dongxu Sun, Michael N. Dudley	2020	36
8	In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii Antimicrobial Agents and Chemotherapy ·Kirk Nelson, Debora Rubio-Aparicio, Ruslan Tsivkovski, Dongxu Sun, Maxim Totrov, Michael Dudley, Olga Lomovskaya	2020	18
9	727. Potency of the β-Lactamase Inhibitor QPX7728 Is Minimally Affected by KPC Mutations that Reduce Potency of Ceftazidime–Avibactam Open Forum Infectious Diseases ·Olga Lomovskaya, Kirk Nelson, Debora Rubio-Aparicio	2019	1
10	Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii International Journal of Antimicrobial Agents ·Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson, Visanu Thamlikitkul, Michael N. Dudley, Татьяна Юрьевна Прокофьева	2018	15
11	Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae Antimicrobial Agents and Chemotherapy ·Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson, Michael N. Dudley, Olga Lomovskaya	2017	137
12	Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity Antimicrobial Agents and Chemotherapy ·Kirk Nelson, Peera Hemarajata, Dongxu Sun, Debora Rubio-Aparicio, Ruslan Tsivkovski, Shangxin Yang, Robert Sebra, Andrew Kasarskis, Hoan Nguyen, Blake Hanson, Shana R. Leopold, George M. Weinstock, Olga Lomovskaya, Romney M. Humphries	2017	137
13	Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections) Open Forum Infectious Diseases ·Olga Lomovskaya, Mariana Castanheira, Nathalie Jullian, Keith S. Kaye, Kirk Nelson, Dongxu Sun, Elizabeth Alexander, Michael N. Dudley, Michael T. Yin	2017	8
14	Minocycline (MINO) Activity Is Enhanced by Polymyxin B (PmB) in TetB Containing Isolates of Acinetobacter baumannii (ACB), Including Those Resistant to PmB Open Forum Infectious Diseases ·Olga Lomovskaya, Kirk Nelson, Debora Rubio-Aparicio, Dongxu Sun, David C. Griffith, Michael N. Dudley	2016	4
15	TetB Testing and Its Absence Identifies Minocycline (MINO) Susceptible Isolates of Acinetobacter baumannii (ACB) Open Forum Infectious Diseases ·Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson, Michael N. Dudley	2016	3
16	Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines Journal of Medicinal Chemistry ·Malahayatie, M.T. Hilgers, Mark L. Cunningham, Bryan P. Kwan, Kirk Nelson, Vickie Brown‐Driver, Voon Ong, Michael Trzoss, Grayson Hough, Karen Joy Shaw, John Finn	2014	66
17	Distinguishing On-Target versus Off-Target Activity in Early Antibacterial Drug Discovery Using a Macromolecular Synthesis Assay SLAS DISCOVERY ·Mark L. Cunningham, Bryan P. Kwan, Kirk Nelson, Daniel C. Bensen, Karen Joy Shaw	2013	31
18	Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity Bioorganic & Medicinal Chemistry Letters ·Chen Cuang, Daniel C. Bensen, Xiaoming Li, Zhiyong Chen, Thanh Lam, Junhu Zhang, Christopher J. Creighton, Mark L. Cunningham, Bryan P. Kwan, Mark A. Stidham, Kirk Nelson, Vickie Brown‐Driver, Victorien Jourdy, Karen Joy Shaw, Felice C. Lightstone, Sergio Wong, Toan B. Nguyen, John Finn, Leslie W. Tari	2012	58
19	Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines Bioorganic & Medicinal Chemistry Letters ·Xiaoming Li, M.T. Hilgers, Mark L. Cunningham, Zhiyong Chen, Michael Trzoss, Junhu Zhang, Ji‐Cheng Yuan, Thanh Lam, K. Thulsi Rao, Beata Gaj, Kirk Nelson, Bryan P. Kwan, Mark A. Stidham, Vickie Brown‐Driver, Karen Joy Shaw, John Finn	2011	50
20	Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors Bioorganic & Medicinal Chemistry Letters ·Leslie W. Tari, Isaac Hoffman, Daniel C. Bensen, Michael J. Hunter, Jay C. Nix, Kirk Nelson, Duncan E. McRee, Ronald V. Swanson	2006	29

About Kirk Nelson

Kirk Nelson is a scholar working on Molecular Medicine, Pollution, Endocrinology, Applied Microbiology and Biotechnology and Pharmacology, having authored 23 papers that have together received 1.2k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (20 papers), Pharmaceutical and Antibiotic Environmental Impacts (9 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers), Bacterial biofilms and quorum sensing (5 papers), Cancer therapeutics and mechanisms (3 papers), Quinazolinone synthesis and applications (2 papers), Infections and bacterial resistance (2 papers) and Berberine and alkaloids research (1 paper). The work is most often cited by research in Molecular Medicine (905 citations), Applied Microbiology and Biotechnology (218 citations), Pharmacology (555 citations), Endocrinology (129 citations) and Pollution (141 citations). Kirk Nelson has collaborated with scholars based in United States and Thailand. Frequent co-authors include Debora Rubio-Aparicio, Dongxu Sun, Michael N. Dudley, Ruslan Tsivkovski, Olga Lomovskaya, David C. Griffith, Olga Lomovskaya, Maxim Totrov, Mark L. Cunningham and Karen Joy Shaw. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Open Forum Infectious Diseases, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters and SLAS DISCOVERY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact